Novaerus develops and sells a patented plasma-based airborne pathogen control technology that reduces airborne bacteria, pathogens, mold, allergens and odors and has been proven effective against MRSA, C‑diff, Norovirus and influenza. Its air sterilization systems are deployed in hundreds of skilled nursing and assisted living facilities across North America and Europe. The company plans to use new capital to capture greater share in the long‑term care market and to establish a position in adjacent healthcare markets. Proceeds will also support product development and innovation, expansion of sales and marketing initiatives, and efforts to drive incremental growth and market share. Oyster Capital Partners is a prior investor and will remain the majority shareholder following the financing. The company frames its technology as delivering measurable financial and clinical benefits to facilities, including lower spending related to airborne illnesses and reduced hospital readmission rates.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2014